Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Gage

Showing results (111-120 of 150) with videos related to

Pageof 15
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|July 19, 2019
Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple MyelomaAng Li, Qian Wu, Suhong Luo, et al.
Journal of Thrombosis and Haemostasis : JTH|May 31, 2022
Standardization of risk prediction model reporting in cancer-associated thrombosis: Communication from the ISTH SSC subcommittee on hemostasis and malignancyKristen M Sanfilippo, Tzu-Fei Wang, Marc Carrier, et al.
Pharmacoepidemiology and Drug Safety|February 9, 2010
Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured populationPeter M Wahl, Keith Rodgers, Sebastian Schneeweiss, et al.
Cardiology Research and Practice|October 24, 2022
Predicting Postoperative Troponin in Patients Undergoing Elective Hip or Knee Arthroplasty: A Comparison of Five Cardiac Risk Prediction ToolsMerih T Tesfazghi, Anne R Bass, Noor Al-Hammadi, et al.
Circulation|March 27, 2012
Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosisBrian R Lindman, Alan Zajarias, José A Madrazo, et al.
JACC. Heart Failure|February 10, 2015
Clinical outcomes with use of erythropoiesis stimulating agents in patients with the HeartMate II left ventricular assist deviceMichael E Nassif, Jayendrakumar S Patel, Jerrica E Shuster, et al.
The New England Journal of Medicine|June 3, 2005
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin doseMark J Rieder, Alexander P Reiner, Brian F Gage, et al.
The Annals of Pharmacotherapy|October 4, 2007
Optimal initial dose adjustment of warfarin in orthopedic patientsPetra A Lenzini, Gloria R Grice, Paul E Milligan, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium|January 24, 2007
Improving adherence to coronary heart disease secondary prevention medication guidelines at a community hospitalThomas C Bailey, Laura A Noirot, Brian F Gage, et al.
Thrombosis and Haemostasis|April 21, 2005
Prospective dosing of warfarin based on cytochrome P-450 2C9 genotypeDeepak Voora, Charles Eby, Mark W Linder, et al.
Pageof 15

Showing results (111-120 of 150) with videos related to

Sort By:
Pageof 15
Journal of the National Comprehensive Cancer Network : JNCCN|July 19, 2019
Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple MyelomaAng Li, Qian Wu, Suhong Luo, et al.
Journal of Thrombosis and Haemostasis : JTH|May 31, 2022
Standardization of risk prediction model reporting in cancer-associated thrombosis: Communication from the ISTH SSC subcommittee on hemostasis and malignancyKristen M Sanfilippo, Tzu-Fei Wang, Marc Carrier, et al.
Pharmacoepidemiology and Drug Safety|February 9, 2010
Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured populationPeter M Wahl, Keith Rodgers, Sebastian Schneeweiss, et al.
Cardiology Research and Practice|October 24, 2022
Predicting Postoperative Troponin in Patients Undergoing Elective Hip or Knee Arthroplasty: A Comparison of Five Cardiac Risk Prediction ToolsMerih T Tesfazghi, Anne R Bass, Noor Al-Hammadi, et al.
Circulation|March 27, 2012
Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosisBrian R Lindman, Alan Zajarias, José A Madrazo, et al.
JACC. Heart Failure|February 10, 2015
Clinical outcomes with use of erythropoiesis stimulating agents in patients with the HeartMate II left ventricular assist deviceMichael E Nassif, Jayendrakumar S Patel, Jerrica E Shuster, et al.
The New England Journal of Medicine|June 3, 2005
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin doseMark J Rieder, Alexander P Reiner, Brian F Gage, et al.
The Annals of Pharmacotherapy|October 4, 2007
Optimal initial dose adjustment of warfarin in orthopedic patientsPetra A Lenzini, Gloria R Grice, Paul E Milligan, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium|January 24, 2007
Improving adherence to coronary heart disease secondary prevention medication guidelines at a community hospitalThomas C Bailey, Laura A Noirot, Brian F Gage, et al.
Thrombosis and Haemostasis|April 21, 2005
Prospective dosing of warfarin based on cytochrome P-450 2C9 genotypeDeepak Voora, Charles Eby, Mark W Linder, et al.
Pageof 15